KRAS-mutation sub-groups analyses have been conducted with three FDA-approved ICIs across multiple lines of therapy, via monotherapy or in combination with chemotherapy, to help explore the predictive effect of KRAS variants in metastatic NSCLC [48,49,50]. Here, KRAS is linked to non-small cell lung carcinoma.